Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Biologics and the Diagnostic Challenges of CTCL and Mycosis Fungoides
Description
The speaker discussed the diagnostic challenges of cutaneous T-cell lymphoma (CTCL), especially mycosis fungoides (MF), in patients treated with biologics. Through several cases, they showed how eruptions initially thought to be eczema or psoriasis worsened, plateaued, or changed on biologic therapy, and how repeat biopsies, molecular studies, and blood work ultimately revealed MF or Sézary syndrome. A key message was that biologics can unmask pre-existing CTCL, accelerate indolent disease, or possibly contribute to a drug-driven process, so persistent or atypical rashes should not simply prompt escalation of treatment. Red flags include late-onset “atopic dermatitis,” atypical distribution, treatment resistance, new morphologic changes, erythroderma, severe pruritus, and nonspecific early biopsies. The speaker emphasized close clinicopathologic correlation, collaboration with experienced dermatopathologists, repeated biopsies when needed, and use of flow cytometry and molecular testing. Overall, the take-home points were that one biopsy is often not enough, biologics should be stopped when suspicion remains high or the disease behaves incorrectly, and not every presumed dermatitis is truly atopic dermatitis or psoriasis.
View moreConclusions
- Biologics can unmask pre-existing cutaneous T-cell lymphoma or accelerate an indolent disease course, so worsening or plateauing skin disease on treatment should prompt renewed suspicion.
- A single negative or nonspecific biopsy is not enough to exclude CTCL when the clinical behavior is atypical, because early disease can be subtle and misleading.
- Clinical red flags such as late-onset dermatitis, atypical distribution, severe pruritus, new morphology, erythroderma, tumors, and poor or partial biologic response should trigger further workup.
- When concern for CTCL exists, clinicians should hold the biologic and repeat evaluation with multiple biopsies, clinicopathologic correlation, TCR clonality studies, and blood flow cytometry when appropriate.
- Delayed recognition and continued incorrect treatment can allow disease progression and make CTCL harder to control.
- Biopsy interpretation requires close collaboration with experienced dermatopathologists because patterns like spongiotic or psoriasiform change do not rule out CTCL.
- Some cases that look like treatment-refractory atopic dermatitis are truly atopic dermatitis, so persistent diagnostic reassessment is necessary rather than assuming every case is lymphoma.
- The safest approach to late-onset or biologic-refractory ‘eczema’ or psoriasis is to treat it as possible CTCL until proven otherwise.
- CTCL DIAGNOSED AFTER BIOLOGICS IS INCREASING. Reported with IL-4, IL-17, IL-23, JAK inhibitors; true incidence unknown; likely under-recognized. Dense line of academic references runs across the bottom, citing multiple dermatology and immunology journals and authors.